Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) — Market Cap & Net Worth
Market Cap & Net Worth: Cumberland Pharmaceuticals Inc (CPIX)
Cumberland Pharmaceuticals Inc (NASDAQ:CPIX) has a market capitalization of $68.47 Million ($68.47 Million) as of June 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20769 globally and #4624 in its home market, demonstrating a -1.92% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cumberland Pharmaceuticals Inc's stock price $5.61 by its total outstanding shares 14983107 (14.98 Million). Review Cumberland Pharmaceuticals Inc (CPIX) financial obligations to assess the company's total debt and financial obligations.
Cumberland Pharmaceuticals Inc Market Cap History: 2015 to 2026
Cumberland Pharmaceuticals Inc's market capitalization history from 2015 to 2026. Data shows change from $78.81 Million to $84.06 Million (-0.20% CAGR).
Index Memberships
Cumberland Pharmaceuticals Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.42 Trillion | 0.00% | #593 of 976 |
|
NASDAQ Composite
IXIC
|
$40.74 Trillion | 0.00% | #2000 of 3165 |
Weight: Cumberland Pharmaceuticals Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Cumberland Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cumberland Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
1.34x
Cumberland Pharmaceuticals Inc's market cap is 1.34 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $82.41 Million | $33.03 Million | -$944.68K | 2.50x | N/A |
| 2017 | $110.28 Million | $41.15 Million | -$7.98 Million | 2.68x | N/A |
| 2018 | $90.35 Million | $40.74 Million | -$6.96 Million | 2.22x | N/A |
| 2019 | $77.16 Million | $34.39 Million | -$3.54 Million | 2.24x | N/A |
| 2020 | $44.20 Million | $37.44 Million | -$3.34 Million | 1.18x | N/A |
| 2021 | $69.97 Million | $35.99 Million | -$3.51 Million | 1.94x | N/A |
| 2022 | $33.71 Million | $42.01 Million | -$5.57 Million | 0.80x | N/A |
| 2023 | $26.85 Million | $39.55 Million | -$6.28 Million | 0.68x | N/A |
| 2024 | $35.51 Million | $37.87 Million | -$6.48 Million | 0.94x | N/A |
| 2025 | $59.63 Million | $44.52 Million | -$2.84 Million | 1.34x | N/A |
Competitor Companies of CPIX by Market Capitalization
Companies near Cumberland Pharmaceuticals Inc in the global market cap rankings as of June 19, 2026.
Key companies related to Cumberland Pharmaceuticals Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #513 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #560 globally with a market cap of $48.78 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #631 globally with a market cap of $43.86 Billion USD ( CN¥299.75 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #634 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #513 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #560 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $43.27 |
| #631 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $43.86 Billion | CN¥46.99 |
| #634 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €13.30 |
Cumberland Pharmaceuticals Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Cumberland Pharmaceuticals Inc's market cap moved from $78.81 Million to $ 84.06 Million, with a yearly change of -0.20%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $84.06 Million | +40.95% |
| 2025 | $59.63 Million | +67.93% |
| 2024 | $35.51 Million | +32.28% |
| 2023 | $26.85 Million | -20.37% |
| 2022 | $33.71 Million | -51.82% |
| 2021 | $69.97 Million | +58.31% |
| 2020 | $44.20 Million | -42.72% |
| 2019 | $77.16 Million | -14.59% |
| 2018 | $90.35 Million | -18.07% |
| 2017 | $110.28 Million | +33.82% |
| 2016 | $82.41 Million | +4.56% |
| 2015 | $78.81 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of Cumberland Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $68.47 Million USD |
| MoneyControl | $68.47 Million USD |
| MarketWatch | $68.47 Million USD |
| marketcap.company | $68.47 Million USD |
| Reuters | $68.47 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Cumberland Pharmaceuticals Inc
Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso… Read more